Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT05951608 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Start date: July 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors

NCT ID: NCT05942378 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors

Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study evaluating the efficacy and safety of HRXG-K-1939 in combination with Adebrelimab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in patients with advanced solid tumors. HRXG-K-1939 will be administered to patients in a dose escalation regimen to determine a recommended dose for expansion.

NCT ID: NCT05906537 Not yet recruiting - Clinical trials for Advanced Solid Tumors

SKB410 for Injection in Solid Tumors

Start date: June 30, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB410 for injection in patients with advanced solid tumors.

NCT ID: NCT05830045 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors

Start date: April 20, 2023
Phase: Phase 1
Study type: Interventional

This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.

NCT ID: NCT05804864 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of KM501 in Patients With Solid Tumors

Start date: April 2023
Phase: Phase 1
Study type: Interventional

A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate HER2

NCT ID: NCT05781048 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

Start date: April 2023
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the efficacy, andsafety of HRS-6209in subjects with advanced solid tumors.To explore the reasonable dosage of HRS-6209.This study also preliminarily evaluated the efficacy of HRS-6209 in patients with advanced solid tumors.

NCT ID: NCT05718219 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Escalating Doses of SIM0348 as a Single Agent in Advanced Solid Tumors

Start date: April 1, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open label, phase I trial to evaluate the safety and tolerability, pharmacokinetic/ pharmacodynamic characteristics and to assess the preliminary efficacy of SIM0348 as monotherapy in adult subjects with advanced and metastatic solid tumors. The trial starts with a dose escalation and dose expansion part (Part 1) followed by a cohort expansion part (Part 2).

NCT ID: NCT05620017 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

Start date: November 2022
Phase: Phase 1
Study type: Interventional

Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.

NCT ID: NCT05609019 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human study with the SYHX2005 tablet primarily designed to evaluate the safety and tolerability of SYHX2005 at increasing doses in patients with advanced solid tumors and for whom no standard of care exists. The study will be conducted in two parts: Stage1 dose-escalation and Stage2 dose-expansion. In Stage1, patient enrolment will be proceeded according to a "Accelerated Titration + BOIN" design in order to identify the maximum-tolerated dose (MTD) or recommended dose. In Stage2, preliminary efficacy response will be assessed in patients with advanced solid tumors in use of the recommended dose.

NCT ID: NCT05509985 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors

Start date: August 9, 2023
Phase: Phase 1
Study type: Interventional

The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent (Part 1) and in combination with pembrolizumab (Part 2) in patients with advanced solid tumors.